On May 18, the U.S. Food and Drug Administration cleared the first test to help determine whether a pregnant woman or a person with swollen lymph nodes testing positive for toxoplasmosis, developed the infection within the past four months.
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2011. Net sales for the period reached €328 million, up a reported 6.8% from €307 million in first-quarter 2010. Growth amounted to 3.5% like-for-like (at constant exchange rates and scope of consolidation).
Innovative system designed by microbiologists for microbiologists helps a growing number of labs achieve substantial productivity gains.
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met today and approved the consolidated financial statements for the year ended December 31, 2010. The meeting was chaired by Jean-Luc Bélingard and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors will be issuing an unqualified opinion in the coming days.
The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care
Combination of Philips’ Magnotech technology and bioMérieux’s assay technology achieves the performance requirements of rapid diagnostic testing in point-of-care applications
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2010.
A world leader in in vitro diagnostics, bioMérieux announces the appointment of James P. Whelan as Executive Vice President of Commercial Services. In this newly created role, he will be responsible for reinforcing bioMérieux’s global service offering. This enhanced offering will include expanded customer lab audits, laboratory accreditation support and comprehensive scientific training programs.
Sepsis progresses quickly, yet rapid test is still largely unavailable in the U.S.
bioMérieux announced today that, as part of a restructuring of its culture media business in the U.S. and Canada, it will phase out the manufacturing of its routine prepared media for clinical applications and will transfer the production of all other products manufactured at its Portland, Oregon site to other locations.
